Trailing-twelve-month (TTM) revenue is $339.59 Million with a year-over-year growth of +51.30%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-26 | $94,732,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2026-01-02 | $57,801,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q1 FY2026Period ended 2026-04-03 | $93,522,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-07-03 | $93,535,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-12 |
| TTM revenue | $339,590,000 |
Current P/S: $1,102,815,164 market capitalization ÷ $339,590,000 TTM revenue = 3.25x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-07-03.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-07-03): $93.53M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T22:23:48.661Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2024-12-27 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2018-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192020-01-03 · USD | FY20202021-01-01 · USD | FY20212021-12-31 · USD | FY20222022-12-30 · USD | FY20232023-12-29 · USD | FY20242024-12-27 · USD |
|---|---|---|---|---|---|---|
| Cataract Intraocular Lenses | N/A | N/A | $13M | $10M | $1M | N/A |
| Implantable Collamer Lenses | $129M | $141M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20132014-01-03 · USD | FY20142015-01-02 · USD | FY20152016-01-01 · USD | FY20162016-12-30 · USD | FY20172017-12-29 · USD | FY20182018-12-28 · USD |
|---|---|---|---|---|---|---|
| China | $9M | N/A | N/A | N/A | N/A | N/A |
| CHINA | N/A | $9M |
$339.59M
$339.59 Million
+51.30%
vs. $224.45M a year ago (TTM)
+10.49%
5 Year compound annual growth rate
1 Year
+51.30%
3 Year
+3.53%
5 Year
+10.49%
10 Year
+15.57%
15 Year
+12.41%
20 Year
+9.88%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $239.44M | ($74.46M) | (23.72%) |
| 2024 | $313.90M | ($8.51M) | (2.64%) |
| 2023 | $322.42M | +$38.02M | +13.37% |
| 2022 | $284.39M | +$53.92M | +23.40% |
| 2021 | $230.47M | +$67.01M | +41.00% |
| 2020 |
TTM Growth
+51.30%
3-Year CAGR
+3.53%
5-Year CAGR
+10.49%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T22:23:48.661Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $270M |
| $319M |
| $313M |
| Intraocular Lenses | $16M | $14M | N/A | N/A | N/A | N/A |
|---|
| Other Surgical Products | $5M | $8M | $5M | $5M | $2M | $1M |
|---|
| $16M |
| $24M |
| $46M |
| FRANCE | N/A | $4M | N/A | N/A | N/A | N/A |
|---|
| Japan | $18M | N/A | N/A | N/A | N/A | N/A |
|---|
| JAPAN | N/A | $19M | $17M | $17M | $17M | $23M |
|---|
| Korea, Republic Of | $8M | N/A | N/A | N/A | N/A | N/A |
|---|
| KOREA, REPUBLIC OF | N/A | $7M | $8M | $7M | $6M | N/A |
|---|
| Other Countries | $20M | $20M | $23M | $32M | $36M | $47M |
|---|
| SPAIN | $5M | $6M | $6M | N/A | N/A | N/A |
|---|
| U S | $13M | N/A | N/A | N/A | N/A | N/A |
|---|
| UNITED STATES | N/A | $11M | $11M | $10M | $8M | $7M |
|---|
| $163.46M |
| +$13.28M |
| +8.84% |
| 2019 | $150.19M | +$26.23M | +21.16% |
| 2018 | $123.95M | +$33.34M | +36.80% |
| 2017 | $90.61M | +$8.18M | +9.92% |
| 2016 | $82.43M | +$5.31M | +6.88% |
